Allergan Receives FDA Clearance For the CoolSculpting® Treatment To Improve Appearance Of Lax Tissue In The Double Chin

Allergan plc (NYSE: AGN) today announced that the CoolSculpting® treatment is the first and only non-surgical fat reduction technology to be FDA-cleared for improved appearance of lax tissue in conjunction with submental fat, or double chin, treatments. CoolSculpting for the double chin is already clinically proven to reduce fat up to 20 percent in the treated area after one treatment.

“Allergan is committed to advancing innovation for CoolSculpting® to meet the needs of patients seeking non-invasive aesthetic treatments,” said David Nicholson, Chief Research and Development Officer at Allergan.

“A 2017 American Society for Dermatologic Surgery (ASDS) survey revealed that 73 percent of patients are bothered by excess fat under the chin. We are pleased this patient concern can successfully be addressed by CoolSculpting through a non-invasive approach, and furthermore improve the appearance of lax tissue in the treated area.”

The Double Approach to the Double Chin

The CoolSculpting® Treatment is the first and only non-surgical fat reduction technology to be FDA cleared for improved appearance of lax tissue after treatment for a double chin.

An 18-week study found that 77 percent of patients visibly showed improved submental tissue laxity.

“In my own patients, I have noticed the improved appearance of lax tissue when using the CoolMini® applicator for the CoolSculpting® system to treat the submental area,” said Jeffrey S. Dover, MD, FRCPC, Co-Director of SkinCare Physicians of Chestnut Hill, Mass. “It is great to see the company invest to validate this and secure the FDA clearance.”